Bosh sahifaFGEN • NASDAQ
add
FibroGen Inc
Yopilish kursi
8,25 $
Kunlik diapazon
8,23 $ - 8,45 $
Yillik diapazon
4,85 $ - 21,88 $
Bozor kapitalizatsiyasi
34,06 mln USD
Oʻrtacha hajm
31,84 ming
Narx/foyda
0,16
Dividend daromadliligi
-
Asosiy maydon
NASDAQ
Bozor yangiliklari
Moliyaviy axborot
Moliyaviy hisobot
Daromad
Sof foyda
| (USD) | sen, 2025info | Y/Y qiyosi |
|---|---|---|
Daromad | 1,08 mln | 774,80% |
Joriy xarajat | 5,30 mln | -43,44% |
Sof foyda | 200,64 mln | 1 274,41% |
Sof foyda marjasi | 18,65 ming | 234,25% |
Har bir ulushga tushum | 49,61 | 13 491,78% |
EBITDA | -5,18 mln | 81,77% |
Amaldagi soliq stavkasi | — | — |
Balans
Jami aktivlari
Jami passivlari
| (USD) | sen, 2025info | Y/Y qiyosi |
|---|---|---|
Naqd pul va qisqa investitsiyalar | 117,98 mln | -9,94% |
Jami aktivlari | 137,01 mln | -48,18% |
Jami passivlari | 119,53 mln | -74,36% |
Umumiy kapital | 17,48 mln | — |
Tarqatilgan aksiyalar | 4,05 mln | — |
Narxi/balansdagi bahosi | -1,96 | — |
Aktivlardan daromad | -8,52% | — |
Kapitaldan daromad | 52,71% | — |
Pul aylanmasi
Naqd pulning sof oʻzgarishi
| (USD) | sen, 2025info | Y/Y qiyosi |
|---|---|---|
Sof foyda | 200,64 mln | 1 274,41% |
Operatsiyalardan naqd pul | -1,85 mln | 77,95% |
Sarmoyadan naqd pul | 87,16 mln | 11 444,37% |
Moliyadan naqd pul | -85,92 mln | -67 551,18% |
Naqd pulning sof oʻzgarishi | -1,87 mln | 80,78% |
Boʻsh pul | 72,84 mln | 1 077,84% |
Haqida
FibroGen, Inc. is a biopharmaceutical company headquartered in San Francisco, California. Once regarded as a promising developer of innovative therapies for anemia and fibrotic diseases, with a market capitalization of roughly $4 billion in 2018–19, the company's value collapsed following late-stage trial failures, regulatory setbacks, and a data manipulation scandal. By 2025, FibroGen was mainly reduced to a single early-stage oncology drug candidate. Wikipedia
Tashkil etilgan
1-yan, 1993
Sayt
Xodimlar soni
225
